Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease - PubMed
6 hours ago
- #Alzheimer's disease
- #preventive therapies
- #target product profiles
- The article discusses the urgent need for target product profiles (TPPs) for therapies aimed at delaying or preventing symptomatic Alzheimer's disease, due to the absence of approved preventive treatments despite scientific advances.
- An international expert group convened by the Global CEO Initiative on Alzheimer's Disease developed TPPs that outline minimum and preferred characteristics for these therapies, including intended use, target populations, safety, and efficacy benchmarks.
- Multiple candidate interventions are currently in clinical trials for at-risk individuals or those with elevated biomarkers but no symptoms, with data expected within 1-2 years, highlighting the importance of stakeholder alignment on therapy characteristics.
- The TPPs provide a foundational framework to accelerate therapeutic development and guide researchers, regulators, and patients in evaluating emerging preventive therapies for Alzheimer's disease.